Today: 20 March 2026
Bath & Body Works stock jumps 5% as BBWI rebounds despite fresh class-action deadline
30 January 2026
1 min read

Bath & Body Works stock jumps 5% as BBWI rebounds despite fresh class-action deadline

NEW YORK, Jan 30, 2026, 15:43 EST — Regular session

Bath & Body Works shares (BBWI) climbed 5.3% to $21.83 during Friday’s afternoon session. The stock fluctuated between $20.38 and $21.99, with roughly 3.4 million shares traded.

U.S. stocks edged higher in a volatile session after Donald Trump nominated Kevin Warsh to succeed Jerome Powell as Federal Reserve chair when Powell’s term ends in May. Investors grappled with a mix of earnings reports and inflation data. “There’s a combination of investor concerns around the Fed chair announcement, some mixed tech earnings and lingering inflation pressure,” said Angelo Kourkafas, senior global strategist at Edward Jones. Reuters

Traders watching Bath & Body Works have spotted a series of law-firm alerts linked to a securities fraud class action. The Schall Law Firm announced that investors who purchased shares between June 4, 2024, and Nov. 19, 2025, can try to become “lead plaintiff” by March 16. This lead plaintiff would have the authority to guide the lawsuit if a judge certifies it as a class action. According to the firm, the complaint claims the retailer misled investors about whether collaborations and promotions were driving sustainable growth, citing alleged breaches of SEC rules. PR Newswire

Shares in beauty and personal care showed varied moves: Ulta Beauty climbed roughly 1.5%, Estée Lauder barely budged, and Coty inched up.

The legal headlines come after a tough period for the retailer. In November, Bath & Body Works shocked with a holiday quarter sales dip, lowered its full-year guidance, and unveiled a transformation plan aiming to save $250 million over two years. The stock plunged almost 24% that same day. Reuters

Friday’s rally gave the shares a boost, but it doesn’t solve the bigger question investors keep asking: how much demand is simply being pulled forward through promotions, and what impact that will have on margins.

But the legal overhang brings its own risks. Securities cases often drag on for months, with mounting costs and management distraction becoming issues long before any court decision.

Investors are watching the broader market closely. Shifts in rate expectations, inflation data, and earnings volatility have been driving sharp moves in consumer stocks, often with little fresh news from the companies themselves.

March 16 marks the deadline for investors to submit their requests to be named lead plaintiff. This decision can significantly influence the pace and intensity of the case moving forward.

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Eaton stock slides late Friday as ETN investors weigh AI data-center push, earnings next week
Previous Story

Eaton stock slides late Friday as ETN investors weigh AI data-center push, earnings next week

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call
Next Story

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Go toTop